Inhibition of Streptozocin-Induced Insulitis and Diabetes With Lobenzarit in CD-1 Mice
- Address correspondence and reprint requests to Dr. Ryuichi Iwakiri, First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka 812, Japan.
When multiple low doses (30 mg/kg body wt) of streptozocin were given to CD-1 mice, diabetes associated with L3T4 T-lymphocyte- and B-lymphocyte-predominant insulitis occurred. Thus, a model of type I (insulin-dependent) diabetes was obtained. To treat these diabetic mice, we administered lobenzarit (CCA), a newly synthesized immunomodulator. CCA (2 or 10 mg/kg body wt) significantly inhibited the progression of diabetes by suppressing the severity and incidence of insulitis. Insulin contents of the pancreas were preserved. The possibility that autoimmune-related diabetes can be treated with CCA warrants further attention.
- Received April 19, 1988.
- Revision received November 21, 1988.
- Accepted November 21, 1988.
- Copyright © 1989 by the American Diabetes Association